Source comparison
Peptides for Post-Surgery Recovery Research: Mechanism Comparison
The table below compares primary peptides under investigation for post-surgical recovery research, their mechanisms, evidence strength, and optimal application contexts. BPC-157 VEGF upregulation, angiogenesis, nitric oxide modulation Strong preclinical, limit
This comparison does not assign a generated winner or score.
- The table below compares primary peptides under investigation for post-surgical recovery research, their mechanisms, evidence strength, and optimal application contexts.
- BPC-157
- VEGF upregulation, angiogenesis, nitric oxide modulation
- Strong preclinical, limited human data
- Tendon/ligament repair, bowel anastomosis, gastric surgery
- 200–500 mcg/day subcutaneous or intraperitoneal
- Best-studied peptide for musculoskeletal and GI surgical recovery; consistent efficacy across models
- TB-500 (Thymosin Beta-4)
- Actin sequestration, cell migration, MMP modulation
- Moderate preclinical, Phase II cardiac data
- Cardiac surgery, dermal wounds, muscle injury
- 2–5 mg twice weekly subcutaneous
- Strong mechanistic rationale; limited but promising human cardiac data
- Ipamorelin / CJC-1295
- Growth hormone secretion, IGF-1 elevation
- Strong clinical data in aging/fracture contexts
- Orthopedic surgery, muscle wasting prevention
- Ipamorelin 200–300 mcg/day; CJC-1295 1–2 mg weekly
- Indirect recovery support via anabolic signaling; well-tolerated with established safety profile
- KPV
- NF-kB inhibition, anti-inflammatory cytokine suppression
- Moderate preclinical (colitis, wound models)
- Abdominal surgery, inflammatory bowel resection
- 1–5 mg/day subcutaneous
- Promising anti-inflammatory profile; limited surgical recovery-specific data
- GHK-CU (Copper Peptide)
- Collagen synthesis, MMP regulation, antioxidant activity
- Moderate dermal wound data
- Plastic surgery, dermal wounds, scar management
- 1–3 mg topical or subcutaneous
- Established in cosmetic contexts; mechanistic fit for surgical scar quality
- Cerebrolysin
- Neurotrophic factor support, anti-excitotoxic effects
- Moderate clinical data in TBI and stroke
- Neurological surgery, spinal procedures
- 10–30 mL IV per protocol
- Neuroprotective rather than regenerative; adjunct to standard neuro-recovery protocols